AMRN Amarin Corp

RNS Number:2600O
Amarin Corporation Plc
19 December 2006



                             AMARIN CORPORATION PLC



LONDON, United Kingdom, December 19, 2006, Amarin Corporation plc ("Amarin" or
"Company") announces that it is sending to its shareholders today a Notice of an
Extraordinary General Meeting of the Company ("Notice of EGM") to be held on
January 25, 2007 relating to a proposal to amend the Company's 2002 Stock Option
Plan. A copy of the Notice of EGM is available on the Company's website at http:
//www.amarincorp.com/financial_reports.cfm.


About Amarin

Amarin is a neuroscience company focused on the research, development and
commercialisation of novel drugs for the treatment of central nervous system
disorders.  Amarin has a late-stage drug development pipeline.  Miraxion,
Amarin's lead development compound, is in Phase III development for Huntington's
disease, Phase II development for depressive disorders and preclinical
development for Parkinson's disease.  Amarin's core development pipeline also
includes the recently acquired global rights to a novel oral formulation of
apomorphine for treating patients with advanced Parkinson's disease.


Miraxion for Huntington's disease is being developed under a Special Protocol
Assessment agreed with the US Food and Drug Administration ("FDA"), has been
granted Fast Track designation by the FDA and has received Orphan Drug
designation in the US and Europe.


Amarin maintains its primary stock market listing in the US on NASDAQ ("AMRN")
and secondary listings in the UK and Ireland on AIM ("AMRN") and IEX ("H2E")
respectively.


For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.


Contacts:

Amarin +44 (0) 207 907 2442

Rick Stewart, Chief Executive Officer

Alan Cooke, Chief Financial Officer

investor.relations@amarincorp.com


Investors:

Lippert/Heilshorn & Associates, Inc. +1 212 838 3777

Kim Golodetz

Anne Marie Fields


Media:

Powerscourt +44 (0) 207 236 5615

Rory Godson

Victoria Brough



Ends




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NOEUKSVRNURUAAA

Amarin (LSE:AMRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Amarin (LSE:AMRN)
Historical Stock Chart
From Feb 2024 to Feb 2025